RU2691698C2 - Антитела против sez6 и способы их применения - Google Patents

Антитела против sez6 и способы их применения Download PDF

Info

Publication number
RU2691698C2
RU2691698C2 RU2014138420A RU2014138420A RU2691698C2 RU 2691698 C2 RU2691698 C2 RU 2691698C2 RU 2014138420 A RU2014138420 A RU 2014138420A RU 2014138420 A RU2014138420 A RU 2014138420A RU 2691698 C2 RU2691698 C2 RU 2691698C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
variable region
complementarity determining
Prior art date
Application number
RU2014138420A
Other languages
English (en)
Russian (ru)
Other versions
RU2014138420A (ru
Inventor
Лаура СОНДЕРС
Скотт Дж. ДИЛЛА
Орит ФУРД
Роберт А. СТАЛЛ
Майкл Торгов
Хой ШАО
Дэвид ЛИУ
Original Assignee
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭББВИ СТЕМСЕНТРКС ЭлЭлСи filed Critical ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Publication of RU2014138420A publication Critical patent/RU2014138420A/ru
Application granted granted Critical
Publication of RU2691698C2 publication Critical patent/RU2691698C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2014138420A 2012-02-24 2013-02-22 Антитела против sez6 и способы их применения RU2691698C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603203P 2012-02-24 2012-02-24
US61/603,203 2012-02-24
PCT/US2013/027476 WO2013126810A1 (en) 2012-02-24 2013-02-22 Anti sez6 antibodies and methods of use

Publications (2)

Publication Number Publication Date
RU2014138420A RU2014138420A (ru) 2016-04-10
RU2691698C2 true RU2691698C2 (ru) 2019-06-17

Family

ID=47790548

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014138420A RU2691698C2 (ru) 2012-02-24 2013-02-22 Антитела против sez6 и способы их применения

Country Status (20)

Country Link
US (3) US9676850B2 (enExample)
EP (2) EP2817339B1 (enExample)
JP (2) JP6401060B2 (enExample)
KR (1) KR102099073B1 (enExample)
CN (2) CN108383909B (enExample)
AU (3) AU2013203506B2 (enExample)
CA (1) CA2865415C (enExample)
CL (2) CL2014002237A1 (enExample)
CO (1) CO7151485A2 (enExample)
ES (1) ES2741936T3 (enExample)
IL (1) IL234208B (enExample)
MX (2) MX373141B (enExample)
MY (1) MY178120A (enExample)
NZ (1) NZ631197A (enExample)
PE (1) PE20150091A1 (enExample)
PH (2) PH12020500604A1 (enExample)
RU (1) RU2691698C2 (enExample)
SG (2) SG10201801444WA (enExample)
WO (1) WO2013126810A1 (enExample)
ZA (1) ZA201406967B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383909B (zh) * 2012-02-24 2021-08-24 艾伯维施特姆森特克斯有限责任公司 抗sez6抗体及使用方法
US11531028B2 (en) * 2013-05-10 2022-12-20 Nordic Bioscience A/S Collagen type X alpha-1 assay
RU2016111139A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
KR20160044042A (ko) * 2013-08-28 2016-04-22 스템센트알엑스 인코포레이티드 부위-특이적 항체 접합 방법 및 조성물
PE20161413A1 (es) * 2013-11-04 2017-01-10 Stemcentrx Inc Conjugados de anticuerpo anti-efna4-farmaco
WO2015084262A2 (en) * 2013-12-03 2015-06-11 Agency For Science, Technology And Research Cytotoxic antibody
EP3101131B1 (en) * 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
KR102240417B1 (ko) 2014-01-29 2021-04-13 케이엠 바이올로직스 가부시키가이샤 항-트랜스티레틴 인간 항체
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
AU2015280436A1 (en) 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
JP6574257B2 (ja) * 2014-10-07 2019-09-11 アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ 新規の抗Ｎｏｄａｌ抗体及びその使用方法
EA201890530A1 (ru) * 2015-08-20 2018-09-28 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
WO2017060976A1 (ja) 2015-10-06 2017-04-13 パイオニア株式会社 光制御装置、光制御方法およびプログラム
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
WO2018071718A1 (en) 2016-10-14 2018-04-19 Nima Labs, Inc. Anti-gliadin antibodies
AU2017344411A1 (en) * 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
EP3559043A4 (en) * 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
EP3424527A1 (de) 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
US11795230B2 (en) 2018-04-13 2023-10-24 Dingfu Biotarget Co., Ltd. Anti-CD27 antibodies and use thereof
CR20200623A (es) * 2018-05-30 2021-07-01 Abbvie Stemcentrx Llc Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
US12091453B2 (en) * 2018-07-11 2024-09-17 Hedgehog, Inc. Epitope specific to SMO protein, antibody recognizing same, and composition comprising same
TWI885529B (zh) 2018-07-31 2025-06-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
TWI840399B (zh) * 2018-08-24 2024-05-01 大陸商江蘇恆瑞醫藥股份有限公司 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
CN114106176B (zh) * 2020-09-01 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
US20230287090A1 (en) * 2020-09-02 2023-09-14 The Feinstein Institutes For Medical Research USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
EP4251209A1 (en) 2020-11-24 2023-10-04 Novartis AG Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
CN113307875B (zh) * 2021-06-10 2022-09-02 福州迈新生物技术开发有限公司 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用
WO2023019174A2 (en) * 2021-08-11 2023-02-16 Apollos Diagnostics, Llc Antibodies to sars-cov-2
KR20250027285A (ko) 2022-05-20 2025-02-25 노파르티스 아게 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법
AU2023270409A1 (en) 2022-05-20 2024-11-21 Novartis Ag Antibody drug conjugates
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
TW202448950A (zh) * 2023-05-08 2024-12-16 大陸商上海翰森生物醫藥科技有限公司 一種抗體或其抗原結合片段、抗體-藥物偶聯物及其應用
CN117736331B (zh) * 2024-02-04 2024-05-07 南昌大学第一附属医院 一种特异性结合psma胞外段的单克隆抗体及其应用
WO2025167503A1 (en) * 2024-02-05 2025-08-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-sez6/b7h3 antibodies and uses thereof
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083552A2 (en) * 2000-04-28 2001-11-08 Eli Lilly And Company Human sez6 nucleic acids and polypeptides

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
ATE320436T1 (de) 1998-08-27 2006-04-15 Spirogen Ltd Dimere pyrrolobenzodiazepine
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
US20030211991A1 (en) 2001-04-17 2003-11-13 Su Eric Wen Human sez6 nucleic acids and polypeptides
CN1343774A (zh) 2001-05-28 2002-04-10 复旦大学 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途
US20040001835A1 (en) 2002-03-04 2004-01-01 Medimmune, Inc. Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP4884224B2 (ja) 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
PT2270010E (pt) 2004-03-01 2012-03-12 Spirogen Ltd Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
JP2009539374A (ja) 2006-06-06 2009-11-19 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 腫瘍性幹細胞が富化された組成物及びそれを含む方法
EP2044120B1 (en) 2006-06-07 2019-01-30 BioAlliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
LT3207941T (lt) 2006-09-07 2020-04-10 Scott & White Memorial Hospital Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
NZ582150A (en) * 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
EP2764874A1 (en) 2007-07-17 2014-08-13 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
WO2010081171A2 (en) 2009-01-12 2010-07-15 Cyntellect, Inc. Laser mediated sectioning and transfer of cell colonies
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
HUE046360T2 (hu) * 2010-03-12 2020-03-30 Debiopharm Int Sa CD37-kötõ molekulák és azok immunkonjugátumai
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
WO2012012801A2 (en) 2010-07-23 2012-01-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
WO2012019060A1 (en) * 2010-08-05 2012-02-09 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
PL3409287T3 (pl) 2010-09-29 2021-09-27 Agensys, Inc. Koniugaty leków i przeciwciał (adc), które wiążą białka 191p4d12
CN108383909B (zh) * 2012-02-24 2021-08-24 艾伯维施特姆森特克斯有限责任公司 抗sez6抗体及使用方法
RU2016111139A (ru) * 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
KR20160044042A (ko) * 2013-08-28 2016-04-22 스템센트알엑스 인코포레이티드 부위-특이적 항체 접합 방법 및 조성물
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
EP3559043A4 (en) 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083552A2 (en) * 2000-04-28 2001-11-08 Eli Lilly And Company Human sez6 nucleic acids and polypeptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUNNERSEN J.M. et al., "Seizure-related gene 6 (Sez-6) in amacrine cells of the rodent retina and the consequence of gene deletion", PLoS One. 2009 Aug 7; 4(8): e6546. OSAKI G. et al., "The distribution of the seizure-related gene 6 (Sez-6) protein during postnatal development of the mouse forebrain suggests multiple functions for this protein: an analysis using a new antibody", Brain Res. 2011 Apr 22; 1386: 58-69. SHIMIZU-NISHIKAWA K. et al., "Cloning and characterization of seizure-related gene, SEZ-6", Biochem Biophys Res Commun. 1995 Nov 2; 216(1): 382-9. РЫБАЛЬСКИЙ Н.Г., СЕРОВА М. А., ИГНАТЬЕВА Г.А., СТАРЧЕУС А.П. "Моноклональные антитела и гибридомы", Москва: ВАСХНИЛ, 1989, стр. 23-44. *
GUNNERSEN J.M. et al., "Seizure-related gene 6 (Sez-6) in amacrine cells of the rodent retina and the consequence of gene deletion", PLoS One. 2009 Aug 7; 4(8): e6546. ИЛ, 1989, стр. 23-44. *
OSAKI G. et al., "The distribution of the seizure-related gene 6 (Sez-6) protein during postnatal development of the mouse forebrain suggests multiple functions for this protein: an analysis using a new antibody", Brain Res. 2011 Apr 22; 1386: 58-69. *
SHIMIZU-NISHIKAWA K. et al., "Cloning and characterization of seizure-related gene, SEZ-6", Biochem Biophys Res Commun. 1995 Nov 2; 216(1): 382-9. *
РЫБАЛЬСКИЙ Н.Г., СЕРОВА М. А., ИГНАТЬЕВА Г.А., СТАРЧЕУС А.П. "Моноклональные антитела и гибридомы", Москва: ВАСХН *

Also Published As

Publication number Publication date
ES2741936T3 (es) 2020-02-12
SG10201801444WA (en) 2018-04-27
IL234208B (en) 2020-11-30
ZA201406967B (en) 2021-06-30
CL2017002823A1 (es) 2018-03-23
PE20150091A1 (es) 2015-02-16
PH12014501914A1 (en) 2014-11-24
US20200181256A1 (en) 2020-06-11
CA2865415A1 (en) 2013-08-29
US20170369571A1 (en) 2017-12-28
AU2018223053B2 (en) 2020-05-14
US20150018531A1 (en) 2015-01-15
HK1205517A1 (en) 2015-12-18
MY178120A (en) 2020-10-05
AU2013203506A1 (en) 2013-09-12
EP3539985A1 (en) 2019-09-18
AU2018223053A1 (en) 2018-09-20
RU2014138420A (ru) 2016-04-10
EP2817339A1 (en) 2014-12-31
MX2020003713A (es) 2020-07-22
KR20150002621A (ko) 2015-01-07
CN108383909B (zh) 2021-08-24
US10533051B2 (en) 2020-01-14
JP6401060B2 (ja) 2018-10-03
CA2865415C (en) 2022-06-21
CN104334580B (zh) 2018-03-30
EP2817339B1 (en) 2019-05-15
CN108383909A (zh) 2018-08-10
SG11201405130UA (en) 2014-11-27
WO2013126810A1 (en) 2013-08-29
CN104334580A (zh) 2015-02-04
AU2013203506B2 (en) 2016-06-09
NZ631197A (en) 2017-05-26
JP2018127469A (ja) 2018-08-16
CO7151485A2 (es) 2014-12-29
AU2016225828A1 (en) 2016-09-22
MX373141B (es) 2020-04-20
AU2016225828B2 (en) 2018-05-31
PH12014501914B1 (en) 2014-11-24
JP2015509948A (ja) 2015-04-02
CL2014002237A1 (es) 2015-05-15
KR102099073B1 (ko) 2020-04-10
PH12020500604A1 (en) 2023-06-14
MX2014010094A (es) 2014-09-16
BR112014020816A2 (pt) 2017-10-10
US9676850B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
RU2691698C2 (ru) Антитела против sez6 и способы их применения
US9931421B2 (en) Methods of delivering DLL3 antibody drug conjugates
US9993566B2 (en) SEZ6 modulators and methods of use
HK1205517B (en) Anti sez6 antibodies and methods of use

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant